Biotech drug developer Ardelyx's Q3 product revenue rises 15%

Ardelyx

30/10/2025 20:18

Overview

Ardelyx Q3 2025 product revenue grows 15% yr/yr to $105.5 mln

IBSRELA Q3 revenue rises 92% yr/yr to $78.2 mln, guidance raised

XPHOZAH Q3 revenue declines yr/yr due to Medicare coverage changes

Outlook

Ardelyx raises 2025 IBSRELA revenue guidance to $270-275 mln

Company expects continued growth for XPHOZAH in Q4 2025

Result Drivers

IBSRELA GROWTH - IBSRELA revenue increased 92% yr/yr to $78.2 mln driven by strong demand and commercial execution

XPHOZAH DECLINE - XPHOZAH revenue declined yr/yr due to Medicare coverage changes, but increased 9% from Q2 2025

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Product Sales
$105.52 mln
Q3 Net Income
-$969,000
Q3 Operating Expenses
$101.68 mln
Q3 Operating Income
$4.67 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Ardelyx Inc is $11.00, about 54.9% above its October 29 closing price of $4.96

Press Release: ID:nGNX56c0X

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)